SomaLogic, Inc. (SLGC) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

SomaLogic, Inc. (SLGC) Healthcare & Pipeline Overview

SomaLogic, Inc. develops protein biomarker identification and clinical diagnostic solutions leveraging its proprietary SOMAmer and SomaScan platform. The U.S.-based enterprise provides services for pharmaceutical discovery, clinical trials, and diagnostic applications in areas like cardiovascular and metabolic diseases, positioning itself in the evolving proteomics and personalized medicine landscape.

What Is the Investment Thesis for SLGC?

SomaLogic, Inc. presents an investment thesis centered on its proprietary proteomics platform, SomaScan, which offers high-throughput protein biomarker identification. A key value driver is the increasing demand for proteomics in drug development and personalized medicine, a market trend noted as a strength for SLGC. The company's ability to simultaneously quantify thousands of proteins in biological samples provides a competitive edge for pharmaceutical and biotechnology clients seeking deeper biological insights. Growth catalysts include expanding its customer base among research and clinical clients, driving adoption of SomaScan services and SomaSignal tests. The application of its technology in diverse therapeutic areas like cardiovascular and metabolic diseases, and NASH, represents significant market opportunities. However, the company operates with a negative profit margin of -111.8%, indicating ongoing profitability challenges. Risks include intense competition from established players and newer technologies in the diagnostics space, requiring continuous innovation and market penetration. Investors should monitor the company's progress in achieving sustained revenue growth and improving financial performance within this evolving market.

Based on FMP financials and quantitative analysis

SLGC Key Highlights

• Market capitalization stands at $0.40 billion, reflecting its current valuation in the market.
• The company reported a gross margin of 55.6%, indicating the profitability of its core services before operating expenses.
• SomaLogic operates with a profit margin of -111.8%, highlighting significant net losses relative to revenue.
• The stock exhibits a Beta of 1.64, suggesting higher volatility compared to the broader market.
• SomaLogic employs 451 individuals, contributing to its research, development, and operational capabilities.

Who Are SLGC's Competitors?

SLGC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SLGC's Key Strengths?

• Proprietary SOMAmer and SomaScan platform for high-throughput protein biomarker identification.
• Increasing interest in proteomics for drug development and personalized medicine.
• Broad application of technology across pharmaceutical R&D and clinical diagnostics.
• Ability to simultaneously detect and quantify numerous proteins in complex biological samples.

What Are SLGC's Weaknesses?

• Negative profit margin of -111.8%, indicating significant unprofitability.
• Reliance on a specialized technology that requires continuous investment in R&D.
• Need to expand customer base and achieve sustained revenue growth.
• High Beta of 1.64 suggests higher stock price volatility.

What Could Drive SLGC Stock Higher?

• Increasing interest in proteomics for drug development and personalized medicine, driving demand for SomaLogic's SomaScan platform.
• Expansion of the customer base among pharmaceutical, biotechnology, and academic research institutions for SomaScan services.
• Potential development and commercialization of new SomaSignal tests as laboratory-developed tests (LDTs) for clinical applications.
• Formation of new strategic partnerships or collaborations to broaden the application and reach of SomaLogic's technology.

What Are the Key Risks for SLGC?

• Negative return on equity (-18.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $8.5M recently.
• Intense competition from established players and newer technologies in the diagnostics space.
• Sustained negative profit margin of -111.8%, indicating challenges in achieving profitability.
• Inability to expand the customer base and achieve sustained revenue growth amid evolving market dynamics.
• Rapid technological advancements by competitors could erode SomaLogic's competitive advantage.
• Regulatory challenges and lengthy approval processes for new clinical diagnostic solutions.

What Are the Growth Opportunities for SLGC?

• Expansion into New Therapeutic Areas: SomaLogic's SomaScan and SomaSignal tests are currently applied across cardiovascular and metabolic diseases, and NASH. Expanding the application of its protein biomarker identification platform into additional high-growth therapeutic areas, such as oncology, neurology, or infectious diseases, represents a significant growth opportunity. This expansion would broaden its addressable market and diversify revenue streams, attracting new pharmaceutical and biotechnology partners seeking advanced proteomic insights for drug discovery and clinical trials.
• Increased Adoption in Pharmaceutical R&D: The growing complexity of drug development necessitates more comprehensive biological insights. SomaLogic's SomaScan platform, which enables simultaneous detection and quantification of numerous proteins, is well-positioned to become an indispensable tool in pharmaceutical and biotechnology R&D pipelines. By demonstrating the platform's utility in identifying novel drug targets, monitoring treatment efficacy, and stratifying patient populations for clinical trials, SomaLogic can drive increased adoption. The global drug discovery market is valued at hundreds of billions of dollars, with a continuous demand for innovative technologies that can accelerate the discovery and development process, presenting a sustained growth timeline for SomaLogic.
• Development of Clinical Diagnostic Applications: Beyond research, the biomarker insights gleaned from SomaScan are instrumental in developing diagnostic applications. Translating these research-use-only (RUO) findings into validated laboratory-developed tests (LDTs) and eventually FDA-approved diagnostics for specific conditions offers a substantial commercial pathway. Focusing on high-prevalence conditions like cardiovascular diseases or metabolic disorders, where early and accurate diagnosis can significantly impact patient outcomes, could unlock a multi-billion dollar diagnostics market. This transition from research tool to clinical diagnostic provider would establish a recurring revenue stream and solidify SomaLogic's position in personalized medicine, with a long-term timeline for regulatory approvals and market penetration.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with major pharmaceutical companies, academic institutions, and other diagnostic providers can significantly accelerate SomaLogic's market penetration and technology adoption. These collaborations could involve co-developing new diagnostic tests, integrating SomaScan into large-scale research initiatives, or licensing the SOMAmer technology for specific applications. Such partnerships provide access to broader customer bases, shared R&D costs, and enhanced credibility within the scientific and medical communities. The proteomics market is highly collaborative, and well-chosen alliances can provide a competitive advantage and expand the reach of SomaLogic's platform into new geographic or application areas over the next 3-5 years.
• Geographic Expansion: While headquartered in the U.S., SomaLogic's global reach can be expanded to capitalize on the increasing demand for advanced proteomics in international markets, particularly in Europe and Asia, where pharmaceutical R&D and personalized medicine initiatives are also rapidly growing. Establishing sales and support infrastructure, or forming distribution partnerships in key international markets, would open new revenue streams. The global diagnostics market is a multi-trillion dollar industry, and even a small share of international expansion could significantly impact SomaLogic's revenue profile. This involves navigating diverse regulatory landscapes and tailoring offerings to regional needs, representing a medium-to-long-term growth strategy.

What Opportunities Does SLGC Have?

• Expansion into new therapeutic areas beyond cardiovascular, metabolic, and NASH.
• Increased adoption of SomaScan services within pharmaceutical and biotechnology companies.
• Development and commercialization of new clinical diagnostic applications (LDTs/FDA-approved).
• Strategic partnerships and collaborations to broaden market reach and technology integration.

What Threats Does SLGC Face?

• Intense competition from established players and newer technologies in diagnostics.
• Rapid evolution of proteomics and diagnostic technologies requiring constant innovation.
• Regulatory hurdles and approval processes for clinical diagnostic products.
• Potential for intellectual property challenges or new entrants with disruptive technologies.

What Are SLGC's Competitive Advantages?

• Proprietary SOMAmer technology: Unique nucleic acid-based reagents designed for specific protein binding.
• Integrated SomaScan platform: Enables simultaneous detection and quantification of numerous proteins in complex samples.
• Extensive biomarker database: Accumulation of protein biomarker signatures from diverse biological specimens.
• Applications in critical areas: Utility in pharmaceutical R&D, clinical trials, and diagnostics for conditions like cardiovascular and metabolic diseases.

What Does SLGC Do?

SomaLogic, Inc., established in 1999 and headquartered in Boulder, Colorado, is a U.S.-based enterprise focused on the identification of protein biomarkers and the development of clinical diagnostic solutions. The company's foundational technology centers on the creation of slow off-rate modified aptamers (SOMAmers), which are unique nucleic acid-based reagents engineered to specifically bind with target proteins. This proprietary technology forms the basis of its SomaScan services, which offer the capability to simultaneously detect and precisely quantify numerous proteins within complex biological samples. The integrated SOMAmer and SomaScan platform is a critical tool for researchers, enabling them to analyze diverse biological specimens and uncover protein biomarker signatures. These insights are invaluable for accelerating pharmaceutical discovery and development initiatives, providing a deeper understanding of drug mechanisms and patient responses. Beyond drug development, the biomarker information derived from SomaScan is instrumental in developing diagnostic applications across a range of significant health conditions. These include cardiovascular diseases, metabolic disorders, nonalcoholic steatohepatitis (NASH), and for broader general wellness monitoring. SomaLogic further extends its offerings with SomaSignal tests, which are available for both research use only (RUO) applications and as laboratory-developed tests (LDTs), catering to a wide spectrum of research and clinical needs. The firm's client base primarily comprises pharmaceutical and biotechnology companies, alongside academic research institutions, reflecting its dual focus on both commercial and scientific advancement. These offerings support various stages of drug development, facilitate the analysis of clinical trials by providing crucial biomarker data, and contribute to novel insights into human biology through the investigation of protein-protein and protein-gene interactions. SomaLogic's position in the healthcare sector is defined by its innovative approach to proteomics, addressing the increasing demand for detailed biological insights in personalized medicine and drug discovery.

What Products and Services Does SLGC Offer?

• Identifies protein biomarkers using proprietary technology.
• Develops clinical diagnostic solutions for various diseases.
• Creates slow off-rate modified aptamers (SOMAmers) for specific protein binding.
• Provides SomaScan services for simultaneous detection and quantification of numerous proteins in biological samples.
• Offers SomaSignal tests for research use only (RUO) and as laboratory-developed tests (LDTs).
• Supports pharmaceutical discovery and development initiatives with biomarker insights.
• Aids in analyzing clinical trials and understanding human biology through protein interactions.
• Catters to pharmaceutical, biotechnology companies, and academic research institutions.

How Does SLGC Make Money?

• Generates revenue by providing SomaScan services for protein biomarker analysis to research and clinical clients.
• Sells SomaSignal tests for both research-use-only and laboratory-developed diagnostic applications.
• Supports pharmaceutical and biotechnology companies in drug development, clinical trial analysis, and biomarker discovery.
• Partners with academic research institutions to advance understanding of human biology and disease.

What Industry Does SLGC Operate In?

SomaLogic, Inc. operates within the dynamic Medical - Healthcare Information Services industry, specifically focusing on proteomics, a rapidly expanding field crucial for understanding disease mechanisms and developing targeted therapies. The increasing interest in proteomics for drug development and personalized medicine represents a significant market trend, positioning SomaLogic's SomaScan platform favorably. This platform, capable of measuring thousands of proteins, addresses the growing need for comprehensive biological insights in pharmaceutical and biotechnology research. The competitive landscape is characterized by established players and emerging technologies in the diagnostics space, necessitating continuous innovation and differentiation for SomaLogic. The company's unique SOMAmer technology provides a distinct approach to protein quantification, aiming to capture market share by offering high-resolution data for both research and clinical applications.

Who Are SLGC's Key Customers?

• Pharmaceutical companies
• Biotechnology companies
• Academic research institutions
• Clinical clients requiring diagnostic applications

How SomaLogic, Inc. Is Valued

SomaLogic, Inc. carries a market capitalization of $396M, placing it in the small-cap category. Relative to its peer group, SLGC's quantitative score of 55/100 is below the peer average of 65/100.

Company Profile

SomaLogic, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Boulder, US. The company is led by CEO Stephen A. Williams BS, MB,. SLGC has traded publicly since 2021.

ROE -19%Key Financial Metrics

Return on equity for SomaLogic, Inc. stands at -18.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -16.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -26.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 13.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -28.3%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

SomaLogic, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.05 places it in the grey zone, a middle ground that warrants monitoring.

Net sellingInsider Activity

The most recent 12 insider filings for SomaLogic, Inc. break down as 12 sales and 0 purchases. On net that is roughly 2.6M shares disposed (about $8.5M), a signal worth weighing alongside the fundamentals.

SLGC Financials

SLGC Latest News

No recent news available for SLGC.

SLGC Analyst Consensus

SLGC MoonshotScore

SomaLogic, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources